Nanobac Pharmaceuticals, Inc. Announces Southern Medical Journal Publication of Nanobacteria Caused Mitral Valve Calciphylaxis.

Business Editors/Health/Medical Writers

TAMPA, Fla.--(BUSINESS WIRE)--March 11, 2004

Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP) ("Nanobac" or "The Company"), announces the publication of independent research which reports that Nanobacteria caused mitral valve calciphylaxis in a man with diabetic renal failure. Dr. Jelic et. al., Department of Pathology, Memorial Hospital, Charleston Area Medical Center, reported in Southern Medical Journal (Volume 97, Number 2, February 2004), the peer reviewed journal of the Southern Medical Association, that Nanobacteria can cause diseases in humans outside the urinary tract. This independent research builds upon the initial discovery by Dr.'s Kajander and Ciftcioglu of Nanobacteria, the smallest known culturable self-replicating life form. Electron Microscopy demonstrated Nanobacteria as an initiator of mitral valve calcific deposits.

"This case study is an excellent example of the potential importance of Nanobacterial infection in life threatening diseases such as calcified heart valves which can lead to an inability of oxygenated blood to be pumped from the heart to the rest of the body," said Alex Edwards, Nanobac's CEO and President. "Diagnosis for the presence of Nanobacteria in these patients may be of help in learning more about this frequently fatal disease."

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at www.nanobaclabs.com or contact us at [e-mail].

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which might cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report, these statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.